A new University of Maryland-led discovery could spur the development of new and improved treatments for Hutchinson-Gilford progeria syndrome (HGPS), a rare genetic disorder with no known cure that causes accelerated aging in children.
J&J’s Tremfya fails giant cell arteritis study, where Roche and AbbVie have succeeded
Johnson & Johnson’s streak of trial wins for its blockbuster drug Tremfya has come to an end. The blockbuster drug failed in a Phase 2
June 26, 2024